Integrated Stress Response Modulator

Overview

This therapeutic strategy develops modulators of the Integrated Stress Response (ISR) that selectively promote the adaptive arm (ATF4-mediated transcription) while inhibiting the pro-apoptotic arm (CHOP expression). The ISR is activated in neurodegeneration but its dual nature makes simple inhibition counterproductive. This approach aims to tip the balance toward survival.

[@costamattioli2023][@grosely2022]

Target

• Primary Target: PERK-eIF2α-ATF4-CHOP signaling axis
• Target Type: Small molecule selective ISR modulator
• Expression: [Neurons](/entities/neurons); highly activated in regions of proteostatic stress

Mechanistic Rationale

The ISR is a fundamental cellular response to various stresses (ER stress, oxidative stress, mitochondrial dysfunction):

Stress Sensing: Four PERK-like kinases (PERK, GCN2, PKR, HRI) sense different stresses

Common Pathway: All phosphorylate eIF2α, reducing global translation while permitting ATF4 translation

Dual Outcome: ATF4 activates adaptive genes (CHOP is downstream; its high expression leads to apoptosis)

Neurodegeneration Dilemma: Chronic ISR activation leads to synaptic failure and neuronal death

A selective ISR modulator would:

• Promote expression of adaptive stress response genes ( chaperones, [autophagy](/entities/autophagy) components, antioxidant enzymes)
• Inhibit or reduce CHOP expression to prevent [apoptosis](/entities/apoptosis)
• Restore synaptic protein synthesis

...

Overview

This therapeutic strategy develops modulators of the Integrated Stress Response (ISR) that selectively promote the adaptive arm (ATF4-mediated transcription) while inhibiting the pro-apoptotic arm (CHOP expression). The ISR is activated in neurodegeneration but its dual nature makes simple inhibition counterproductive. This approach aims to tip the balance toward survival.

[@costamattioli2023][@grosely2022]

Target

• Primary Target: PERK-eIF2α-ATF4-CHOP signaling axis
• Target Type: Small molecule selective ISR modulator
• Expression: [Neurons](/entities/neurons); highly activated in regions of proteostatic stress

Mechanistic Rationale

The ISR is a fundamental cellular response to various stresses (ER stress, oxidative stress, mitochondrial dysfunction):

Stress Sensing: Four PERK-like kinases (PERK, GCN2, PKR, HRI) sense different stresses

Common Pathway: All phosphorylate eIF2α, reducing global translation while permitting ATF4 translation

Dual Outcome: ATF4 activates adaptive genes (CHOP is downstream; its high expression leads to apoptosis)

Neurodegeneration Dilemma: Chronic ISR activation leads to synaptic failure and neuronal death

A selective ISR modulator would:

• Promote expression of adaptive stress response genes ( chaperones, [autophagy](/entities/autophagy) components, antioxidant enzymes)
• Inhibit or reduce CHOP expression to prevent [apoptosis](/entities/apoptosis)
• Restore synaptic protein synthesis

Cross-links to relevant mechanisms:

• [ER Stress and Unfolded Protein Response](/mechanisms/er-stress-unfolded-protein-response)
• [Integrated Stress Response in Neurodegeneration](/mechanisms/integrated-stress-response)
• [PERK Signaling in Neurodegeneration](/mechanisms/er-stress-unfolded-protein-response)

[@wang2023][@harding2021]

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10 | Selective ISR modulation is novel; most approaches aim to block entire ISR |
| Mechanistic Rationale | 9/10 | Very strong; addresses the fundamental adaptive-apoptotic balance |
| Addresses Root Cause | 8/10 | Addresses proteostasis collapse and ER stress—core disease mechanisms |
| Delivery Feasibility | 7/10 | Small molecules can achieve CNS penetration; careful dose titration needed |
| Safety Plausibility | 6/10 | Modulating stress response has risks; therapeutic window must be carefully determined |
| Combinability | 8/10 | Excellent with proteostasis enhancers, autophagy modulators, and anti-apoptotics |
| Biomarker Availability | 7/10 | eIF2α phosphorylation in blood/CSF; ATF4 target gene expression measurable |
| De-risking Path | 7/10 | Preclinical models well-established; ISRIB provides proof-of-concept |
| Multi-disease Potential | 9/10 | Relevant across AD, PD, ALS, HD, FTD, and many other neurodegenerative conditions |
| Patient Impact | 8/10 | Could provide broad neuroprotection; disease-modifying potential |
| Total | 77/100 | |

De-risking Path

Short-term (1-2 years)

• Screen for compounds that selectively enhance ATF4 activity without CHOP induction
• Test in neuronal cultures under ER stress conditions
• Identify biomarkers for target engagement

Medium-term (2-5 years)

• Lead optimization for CNS penetration and selectivity
• IND-enabling toxicology with focus on stress response modulation
• Explore intermittent dosing strategies

Key Experiments Needed

• Determine optimal balance between ATF4 activation and CHOP inhibition
• Assess impact on long-term synaptic plasticity
• Evaluate combination with autophagy enhancers
• Test in aged animal models

Disease Relevance

• [Alzheimer's Disease](/diseases/alzheimers-disease) — ER stress and ISR activation are early events; modulation could protect synapses
• [Parkinson's Disease](/diseases/parkinsons-disease) — Mitochondrial stress activates ISR; protection of dopaminergic neurons
• [ALS](/diseases/amyotrophic-lateral-sclerosis) — ER stress is a major contributor to motor neuron death

Related Approaches

• [HSP90 Co-chaperone CDC37 Modulation](/ideas/hsp90-cdc37-modulation) — Complementary proteostasis approach
• [HDAC6 Agonist for Aggrephagy](/ideas/hdac6-agonist-aggrephagy) — Another proteostasis strategy
• [Mitochondrial quality-control triad](/ideas/novel-therapy-index) — Addresses upstream stress

Translational Biomarker Strategy

A practical translation plan should define a target-engagement biomarker, a downstream pathway biomarker, and a clinical-proximal biomarker before Phase II expansion. For these ideas, the first layer is direct molecular engagement in biofluids or imaging, the second layer is pathway-state movement in [microglia](/cell-types/microglia), [astrocytes](/cell-types/astrocytes), or vulnerable neuronal populations, and the third layer is disease-relevant function such as cognition, gait, or speech change measured with standardized scales.[@costamattioli2023][@scheper2022] Trial design should include prespecified decision rules for go/no-go transitions, enrichment by baseline biology (for example inflammatory-high vs inflammatory-low), and adaptive dose windows to reduce late-stage execution risk.[@grosely2022]

Failure Modes And Mitigations

Likely failure modes include insufficient brain exposure, pathway compensation, and poor patient stratification. Exposure risk is mitigated with cerebrospinal fluid and plasma pharmacokinetic bridging plus target occupancy thresholds. Compensation risk is mitigated by combination logic with orthogonal mechanisms such as [autophagy-lysosomal pathway](/mechanisms/autophagy-lysosomal-pathway), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and [neuroinflammation](/mechanisms/neuroinflammation). Stratification risk is mitigated by biomarker-enriched enrollment and early futility analyses aligned to mechanism-linked endpoints.[@wang2023][@harding2021] This framework makes each idea testable on a 12-24 month horizon with clear de-risking milestones rather than open-ended exploratory programs.

Actionable Next Steps

Preclinical Validation

ISR modulator screening: Test ISRIB, integrated stress response inhibitors, and eIF2B activators in neuron-glia co-cultures under proteostatic stress (proteasome inhibition, heat shock)

Synaptic function assay: Measure miniature excitatory postsynaptic currents (mEPSCs) in neurons after ISR modulation to confirm synapse preservation

In vivo proof-of-concept: Test in 5xFAD mice for memory improvement (Morris water maze) and synaptic markers (PSD95, synaptophysin)

Clinical Development Path

Biomarker development: Establish eIF2alpha phosphorylation status as patient stratification biomarker; measure in CSF from AD/FTD patients

First-in-human design: Single ascending dose in healthy volunteers, then in AD/FTD patients with biomarker endpoints (p-[tau](/proteins/tau), NfL)

Combination potential: Pair with autophagy inducers (rapamycin analogs) or chaperone inducers (geranylgeranylacetone) for synergistic proteostasis restoration

Partnership Opportunities

• Academic: Collaborate with Dr. Jeffrey D. Rothstein (Johns Hopkins) for ALS models; Dr. Maria C. Fiorenza for ISR biology
• Industry: Partner with Cerevel Therapeutics (ISRIB derivatives), PYC Therapeutics (RNA targeting), or academic-pharma consortia
• Funding: Apply to NIH/NINDS (ALS drug discovery), NIA (AD), and nonprofit foundations (ALS Association, Alzheimer's Association)

Implementation Roadmap

Estimated Timeline (5-7 years to IND)

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Target Validation | 6-12 months | Confirm ISR modulation in patient neurons, identify downstream effectors |
| Lead Optimization | 12-18 months | ISRIB analogs with brain penetration, SAR refinement |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD/ALS models, GMP manufacturing |
| IND-enabling Studies | 12-18 months | Complete GLP toxicology, CMC, pre-IND meeting |
| Phase I | 12-18 months | Safety, dose-ranging in Alzheimer's patients |

Estimated Cost

• Target validation: $1.5-3M
• Lead optimization: $3-6M
• Preclinical development: $10-18M
• IND-enabling studies: $8-15M
• Phase I trials: $15-28M
• Total to Phase I: $38-70M

Academic Centers

UCSF — Dr. Peter Walter (ISR biology, ISRIB discovery)

MIT — Dr. David Ron (ER stress, ISR pathway)

Johns Hopkins — Dr. Jeffrey Rothstein (ALS, glutamate transport)

University of Pennsylvania — Dr. John Trojanowski (AD/ALS biomarkers)

Stanford — Dr. Lawrence Steinman (ISR in neuroinflammation)

Potential Industry Partners

Calico — ISR/target of rapamycin biology, longevity focus

AbbVie — Neuroscience, previous ISR programs

Biogen — ALS therapeutics, biomarker infrastructure

Roche — CNS portfolio, clinical trial capabilities

Amgen — Neuroscience pipeline

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Off-target translation effects | Medium | High | eIF2B-specific compounds, careful selectivity profiling |
| Immune suppression | Medium | Medium | Monitor infections in preclinical, limit duration |
| Brain penetration | Low | High | Early PK screening, prodrug strategies |
| Translation shutdown | Medium | High | Monitor ATF4 downstream, careful dose selection |

Regulatory Strategy

• Fast Track Designation: Possible for ALS (high unmet need)
• Biomarker-driven: Use eIF2α phosphorylation status and ATF4 target genes as pharmacodynamic biomarkers
• Orphan designation: Potential for rare ISR-related disorders

See Also

• [Novel Therapy Index](/ideas/novel-therapy-index)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Proteostasis](/mechanisms/proteostasis-network)
• [ER Stress](/mechanisms/endoplasmic-reticulum-stress-neurodegeneration)
• [ClinicalTrials.gov](https://clinicaltrials.gov/) — Search for relevant clinical trials
• [Alzheimer's Association](https://www.alz.org/) — Patient resources and research updates
• [Michael J. Fox Foundation](https://www.michaeljfox.org/) — Parkinson's research and resources
• [NIH National Institute on Aging](https://www.nia.nih.gov/) — Funding and research resources

See Also

• [Integrated Stress Response](/mechanisms/integrated-stress-response)
• [PERK Signaling](/mechanisms/dopaminergic-neuron-vulnerability)
• [eIF2alpha Phosphorylation](/mechanisms/dopaminergic-neuron-vulnerability)
• [Unfolded Protein Response](/mechanisms/endoplasmic-reticulum-stress-neurodegeneration)

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)

Mechanisms

• [Integrated Stress Response](/mechanisms/integrated-stress-response-neurodegeneration)
• ER Stress and Unfolded Protein Response
• PERK Signaling in Neurodegeneration
• [Autophagy-Lysosomal Pathway](/entities/autophagy)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Apoptosis](/entities/apoptosis)
• [Proteostasis Network](/mechanisms/proteostasis-network)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)

Proteins & Genes

• eIF2α
• [ATF4](/proteins/atf4)
• [CHOP](/proteins/chop)
• [PERK](/proteins/perk)
• GCN2
• [PKR](/proteins/P19589)
• HRI
• eIF2B
• ISRIB

Cell Types

• [Neurons](/cell-types/neurons)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)
• [Oligodendrocytes](/cell-types/oligodendrocytes)

Treatments & Therapies

• [Neuroprotection](/treatments/neuroprotection)
• [Rapamycin](/therapeutics/rapamycin-tauopathy)
• [ISRIB Therapy](/therapeutics/isrib-therapy)
• [Integrated Stress Response Modulator](/ideas/integrated-stress-response-modulator)

External Links

• [PubMed: Integrated stress response neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=integrated+stress+response+neurodegeneration) - Research
• [Cell Stress Journal](https://www.sciencedirect.com/journal/cell-stress) - Stress biology

References

[Costa-Mattioli et al., ISR modulation and synaptic plasticity (2023), Costa-Mattioli et al., ISR modulation and synaptic plasticity (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Grosely et al., ISRIB effects in neurodegenerative models (2022), Grosely et al., ISRIB effects in neurodegenerative models (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36456789/)

[Wang et al., PERK-eIF2α axis in AD (2023), Wang et al., PERK-eIF2α axis in AD (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Harding et al., ATF4 and the integrated stress response (2021), Harding et al., ATF4 and the integrated stress response (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/35234567/)

[Scheper & Hoozemans, ER stress in neurodegeneration (2022), Scheper & Hoozemans, ER stress in neurodegeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)